Navigation Links
Representative Scott Peters Visits Avelas Biosciences
Date:11/20/2015

SAN DIEGO, Nov. 20, 2015 /PRNewswire/ -- Today U.S. Congressional Representative (CA-52) Scott Peters toured Avelas Biosciences, a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment. During the visit, he met with local entrepreneurs from Avelas, Avalon Ventures and COI Pharmaceuticals as well as medical innovators from UCSD.

"It was a privilege to host Representative Peters at Avelas Biosciences today," said Carmine Stengone, president and CEO of Avelas Biosciences. "We appreciate all the work he has done to support medical innovation and the opportunity to showcase our disruptive technology designed to improve cancer surgery and therapeutic targeting. Avelas is a true San Diego biotech innovation story, with San Diego technology, investors, entrepreneurs and medical innovators."

Avelas Biosciences was founded by Avalon Ventures on technology from the lab of Nobel laureate Roger Y. Tsien, Ph.D., professor of chemistry, biochemistry and pharmacology at UC San Diego. It is headquartered at COI Pharmaceuticals, Avalon's Community Of Innovation. Avelas is developing AVB-620, a fluorescent, cancer "illuminator" that is designed to enable surgeons to distinguish tumor tissue from normal during surgery. AVB-620 is in clinical trials for breast cancer under the leadership of Anne Wallace, M.D., director of the Comprehensive Breast Health Center at Moores Cancer Center at UC San Diego Health.

"At UC San Diego, we are committed to translating science discovered in the lab to our cancer patients, to providing access to new and often dramatic technologies through early clinical trials," said Dr. Wallace. "This partnership between science, clinicians and the community allows us to help bring forward improvements in cancer care for patients here and around the world."

Representative Peters stated, "Avelas, Avalon and the Community Of Innovation are more examples of San Diego's leadership in the fields of bioscience and biotechnology. The collaborative approach I saw here today is what sets San Diego apart and why the research performed in San Diego is recognized around the world."

Earlier this month, Representative Peters was honored by the Healthcare Leadership Council as a "Champion of Healthcare Innovation" in recognition of his support of patient-centered medical progress.

About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. Lead candidate AVB-620 is in phase 1b trials in up to 39 breast cancer patients, assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. Avelas was founded by Avalon Ventures on technology from Nobel laureate Roger Y. Tsien, Ph.D.  For additional information, please visit www.avelasbio.com.

University of California Disclaimer
The information stated above was prepared by Avelas Biosciences Inc. and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of Avelas Biosciences, Inc. or any of its products, by The Regents of the University of California, its officers, agents and employees.

 


'/>"/>
SOURCE Avelas Biosciences
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc.
2. Alabama Lyme Disease Association Has Representation on Commission Established by the Alabama House of Representatives to Study Lyme Disease and Other Tick-Borne Illnesses
3. The Return of Extinct Animals – and Maybe Humans; Latest Topic by HuffPost Columnist and Sociologist Gini Graham Scott
4. TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
5. Scottish Scientists Lead This Years Life Science Discoveries
6. Regenesis Biomedical Names Scott Brooks Chief Executive Officer
7. RRD International Names J. Scott Tarrant President
8. Masy Systems Adds Scott Suttinger as Product Manager of DataTrace Dataloggers and Equipment Rentals
9. Three World-Renowned Philadelphia Scientists Are Named As Recipients Of The 2013 John Scott Award
10. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
11. Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2020)... ... August 06, 2020 , ... ... industries, announces it has closed on the purchase of greenfield for a new, ... TX and includes over 21 acres in the initial acquisition, with an option ...
(Date:7/31/2020)... Texas (PRWEB) , ... July 29, 2020 , ... ... solutions today announced the launch of its new tagline, “BUILDING FOR LIFE.” The ... biopharmaceutical industry and around the globe, requiring fast track capacity to provide patients ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... eSource has ... inefficiencies. This webinar will cover the history of eSource, the reasons it did not ... EMR/EHR to wearables, to site source, the industry is moving towards capturing data electronically ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and catheter implantation, the ... is only the beginning of a successful study, while protecting and accessing the catheter ... Global Head of Surgery from Envigo in a live webinar ...
Breaking Biology Technology:
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently ... ideal for public health agencies of all sizes. With a focus on tracking ... individuals find appropriate health care, Mosio helps public health departments automate communications and ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the ... ProText™, making them the first Wharton’s jelly allografts to be assigned a Q code ... solutions are the first Wharton’s jelly allograft product to be recognized as a 361 ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski ... with a near term focus on Type 2 diabetes and associated comorbidities. , ... multiple therapeutic areas and classes. As Chief Commercial Officer, Justin will lead ...
Breaking Biology News(10 mins):